Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2014 13:30 ET | Source: Immunomedics, Inc.

Immunomedics Reports Results With IMMU-132 in Patients With Pancreatic Cancer

NEW ORLEANS, May 20, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported a stabilization of disease, as measured by computed tomography (CT) according to RECIST criteria, in...
May 19, 2014 11:00 ET | Source: Immunomedics, Inc.

Immunomedics Reports Updated Results With 90Y-Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer

-- Overall Survival of 7.9 Months in Patients Receiving Multiple Cycles of Treatment in Combination of Low-Dose Gemcitabine – -- Results Presented at Press Conference of American Association...
May 15, 2014 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present Updated Phase II Results From Antibody-Drug Conjugate Programs at 2014 ASCO

MORRIS PLAINS, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), today announced that five posters on its product candidates will be presented at the 2014 Annual Meeting of the...
May 13, 2014 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces U.S. Patent for IMMU-114

MORRIS PLAINS, N.J., May 13, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. patent no. 8,722,047 for the Company's patent application "Humanized...
May 07, 2014 16:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2014 Results and Clinical Program Developments

MORRIS PLAINS, N.J., May 7, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported financial results for the third quarter ended March 31, 2014. The Company also highlighted recent...
May 07, 2014 16:01 ET | Source: Immunomedics, Inc.

Immunomedics Closes $30 Million Public Offering of Common Stock

MORRIS PLAINS, N.J., May 7, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has closed its recently announced underwritten public offering of nine million shares of...
May 05, 2014 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2014 Financial Results

MORRIS PLAINS, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, May 8, 2014 at 10:00 a.m....
May 02, 2014 09:20 ET | Source: Immunomedics, Inc.

Immunomedics Prices $30 Million Public Offering of Common Stock

MORRIS PLAINS, N.J., May 2, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the pricing of an underwritten public offering of 9 million shares of its common stock, offered...
May 01, 2014 16:01 ET | Source: Immunomedics, Inc.

Immunomedics Announces Proposed Public Offering of Common Stock

MORRIS PLAINS, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it is offering to sell, subject to market and other conditions, shares of its common stock...
April 23, 2014 12:30 ET | Source: Immunomedics, Inc.

Immunomedics Highlights Clinical Pipeline for Solid Cancer and Lupus Therapy at R & D Day

MORRIS PLAINS, N.J., April 23, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted...